Halozyme Therapeutics Inc (HALO) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $69.22
• Market Cap: $8.30B
• P/E Ratio: 27.48
• EPS: $2.56
• 52-Week High: $82.22
• 52-Week Low: $47.50

Market Sentiment

Halozyme Therapeutics Inc currently has a Neutral sentiment score of 0.02.

About Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc. is an innovative biopharmaceutical company headquartered in San Diego, California, recognized for its groundbreaking drug delivery technologies that significantly enhance the effectiveness of existing therapies. Utilizing its proprietary ENHANZE® technology, Halozyme focuses on developing subcutaneous formulations that improve patient adherence and outcomes across a range of indications. The company strategically collaborates with industry-leading pharmaceutical pa...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Halozyme Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does HALO pay dividends?

Halozyme Therapeutics Inc (HALO) does not currently pay a regular dividend.

What is HALO's P/E ratio?

Halozyme Therapeutics Inc has a price-to-earnings (P/E) ratio of 27.48.

What is HALO's market cap?

Halozyme Therapeutics Inc (HALO) has a market capitalization of $8.30B with a current stock price of $69.22.